MedTrace Logo

META 10-19 in Patients With Relapsed/Refractory Autoimmune Hemolytic Anemia

NCT07689604 · Status: NOT_YET_RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2026-07-08

No results posted yet for this study

Summary

A Study of Metabolically Armed Autologous CD19 CAR T-Cell Therapy (META 10-19) in Patients with Relapsed/Refractory Autoimmune Hemolytic Anemia

Conditions

  • Autoimmune Hemolytic Anemia (AIHA)

Interventions

BIOLOGICAL

Metabolically Armed Autologous CD19 CAR T-Cell therapy

Metabolically Armed Autologous CD19 CAR T-cells. Each subject receive metabolically autologous armed CD19 CAR T-cells by intravenous infusion.

Sponsors & Collaborators

  • Hangzhou Leman Biotech Co., Ltd

    collaborator UNKNOWN

  • Institute of Hematology & Blood Diseases Hospital, China

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-08
Primary Completion
2027-05-01
Completion
2028-10-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07689604 on ClinicalTrials.gov